Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Cullinan Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -40.18%, provide a clear picture of how effectively CGEM converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CGEM competes directly with industry leaders such as SPRY and AMPH. With a market capitalization of $915.68M, it holds a significant position in the sector. When comparing efficiency, CGEM's gross margin of N/A stands against SPRY's 74.80% and AMPH's 46.79%. Such benchmarking helps identify whether Cullinan Therapeutics Inc is trading at a premium or discount relative to its financial performance.
